East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more East Resources Acquisition Charts. Click Here for more East Resources Acquisition Charts.](/p.php?pid=staticchart&s=N%5EERES&p=8&t=15)
eResearchTechnology and Mortara Instrument Enter into a Strategic
Alliance to Provide Enhanced Digital ECG Products and Services
Agreement to Provide eRT with a Virtual Manufacturing Partner; eRT will Market
Proprietary Products to Global Drug Developers
PHILADELPHIA, July 27 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), (NASDAQ:ERES), a leading provider of centralized electrocardiographic
(ECG) collection and interpretation services, announced today a strategic
agreement with Mortara Instrument, Inc., a leading provider of ECG technologies
and architect of the E-Scribe ECG Warehouse designed for the United States Food
and Drug Administration ("FDA") Center for Drug Evaluation and Research. The
agreement includes production of an eRT branded digital ECG collection device,
appoints eRT as the exclusive ECG core laboratory reseller of Mortara's
E-Scribe ECG Warehouse Services, and designates eRT an authorized reseller of
Mortara collection devices to the global drug development industry.
Key details of this comprehensive agreement include:
-- Production of an eRT private label digital ECG collection device based
on the new Mortara ELI 150 Rx 12-lead resting ECG technology platform.
eRT will be first to market with an ELI 150 Rx-based solution, which
features an advanced design optimized for clinical research. The
agreement provides a mechanism for close design and engineering
collaboration between eRT and Mortara to drive ongoing improvements to
the eRT private label digital ECG collection platform, including tight
integration with eRT's EXPeRT(R) workflow enabled data handling
technology, the first solution in production that was designed
explicitly to meet emerging international regulatory guidance and
technical standards. The eRT private label line will be available in
the fourth quarter.
-- Designation of eRT as an authorized reseller of Mortara digital ECG
collection devices to the global drug development industry. eRT will
serve as a fulfillment channel for demand from the global drug
development community to purchase or rent Mortara digital ECG
collection devices. In addition, eRT will work with sponsors that
have selected eRT to perform ECG core laboratory services and prefer
to purchase digital ECG collection devices from eRT as opposed to
renting units on a trial-by-trial basis. eRT will offer equipment
purchasers its industry leading site support and logistics services,
including dedicated warehouse and repair/replacement services.
-- Designation of eRT as the exclusive ECG core laboratory reseller of
Mortara's E-Scribe ECG Warehouse Services. With the addition of
Mortara's E-Scribe ECG Warehouse Services, eRT will be able to offer
drug developers full lifecycle solutions that include the ability for
sponsors to view and manage annotated ECGs as well as to proactively
review ECG waveforms for significant outliers utilizing the Mortara
toolset designed specifically for the FDA review process. The
identification of outliers will be made by scoring algorithms
developed by Mortara under a Cooperative Research and Development
Agreement (CRADA) with the FDA executed in June 2004 to create the
digital ECG warehouse.
"This landmark agreement brings several sustainable competitive advantages to
eRT and its customers that will drive better outcomes for cardiac safety
services in new drug development and reinforces eRT's global industry
leadership in technology, capability and capacity to meet growing demand," said
Scott Grisanti, senior vice president of business development and chief
marketing officer at eRT. "First, availability of an eRT branded digital ECG
collection device will allow eRT to enjoy scale economies that support our
ongoing strategy to deliver best value to our customers and continuously raise
the bar for service through tighter integration between digital ECG collection
and eRT's EXPeRT(R) processing platform. Second, the authorized reseller
arrangement allows eRT to assist drug developers to implement new strategies
that institutionalize digital ECG collection and central processing across all
phases of clinical research.
"Further, being named exclusive ECG core laboratory reseller of the Mortara
E-Scribe ECG Warehouse will ensure that this cutting edge solution delivers
optimal market value by leveraging the global reach of eRT's consultative
business development organization. Also, the reseller arrangement builds on
earlier collaboration between eRT, Mortara, and A.M.P.S., LLC (AMPS) on the
development of the standard, annotated digital ECG submission format used as
the foundation of the Warehouse. Executives from eRT, Mortara and AMPS were
recognized for their collaboration on the digital ECG waveform standard with an
FDA Commissioner's Special Citation in 2003."
Dr. Justin L. Mortara, vice president of Mortara Instrument commented, "This
strategic agreement between eRT and Mortara offers substantial value to the
drug development community by combining Mortara's leadership in the design and
delivery of the premier digital ECG collection platform for use in clinical
research with eRT's global reach and market presence. The agreement
demonstrates Mortara's understanding of the unique requirements of ECG central
laboratories and a willingness to develop solutions for their specific needs.
It also establishes a foundation for collaborative research and development
between the organizations that will allow ongoing optimization of Mortara's
technology by channeling feedback from eRT's unmatched experience and customer
base in the clinical trials arena. eRT's role as the E-Scribe ECG Warehouse
reseller will complement Mortara's direct ECG Warehouse service offering and
allow the industry to derive maximum benefit in choosing digital ECG
technologies to expedite the new drug candidate review and approval process."
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.
Based in Milwaukee, WI, Mortara Instrument, Inc. is distinguished in the field
of non-invasive cardiology for innovations that are the core of the company's
complete line of ECG products including electrocardiographs, stress exercise
systems, Holter systems, data warehousing solutions, and cardiology monitoring
systems. The company's website is http://www.mortara.com/.
Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development and market demand. As a result, actual
results may differ materially from any financial outlooks stated herein.
Further information on potential factors that could affect the company's
financial results can be found in the company's Reports on Forms 10- K and 10-Q
filed with the Securities and Exchange Commission.
DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473, or
Matt Hayden, Hayden Communications, +1-858-704-5065, for eResearchTechnology
Web site: http://www.mortara.com/
Web site: http://www.ert.com/